Opinion

Video

Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

Experts evaluate the frequency of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T therapy, comparing their incidence to that observed with other immunotherapies such as bispecific antibodies.

Video content above is prompted by the following:

  • How frequently do you see severe CRS and ICANs with CAR-T, and how does that compare to other therapies like Bispecific-Antibodies?
  • Does developing severe CRS or ICANS correlate with long-term outcomes?
  • Are there risk factors that can predict those who are at higher risk for developing severe CRS and/or ICANs?
Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma